Yannan Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yannan Jiang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Changming Huang
B Department of Gastric Surgery , Fujian Medical University Union Hospital , Fuzhou , China
1 shared publication- Hai Huang
Department of Breast and Thyroid Surgery The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University Suzhou China
1 shared publication Jianhua Zhu
A Department of Gastrointestinal Surgery , Suzhou Municipal Hospital, Nanjing Medical University , Suzhou , China
1 shared publicationJin‐Yan Liu
Department of Breast and Thyroid Surgery The Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University Suzhou China
1 shared publicationJun Lu
B Department of Gastric Surgery , Fujian Medical University Union Hospital , Fuzhou , China
1 shared publicationLin‐Feng Tao
Department of Critical Care Medicine the Affiliated Suzhou Hospital of Nanjing Medical University, Gusu School, Nanjing Medical University Suzhou China
1 shared publication
Latest Publications
- Open Access
- 12 June 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (14) , 15704-15719
Construction of a prognostic model for triple‐negative breast cancer based on immune‐related genes, and associations between the tumor immune microenvironment and immunological therapy
Background: Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the worst prognosis, and it is highly heterogeneous. There is growing evidence that the tumor immune microenvironment (TIME) plays a crucial role in tumor development, maintenance, and treatment responses. Notably however, the full effects of the TIME on prognosis, TIME characteristics, and immunotherapy responses in TNBC patients have not been fully elucidated. Methods: Gene Expression Omnibus and The Cancer Genome Atlas data were used to data analysis. Single-cell sequencing and tissue microarray analysis were used to investigate gene expression. The concentrations and distributions of immune cell types were determined and analyzed using the CIBERSORT strategy. Tumor immune dysfunction and exclusion score and the IMvigor210 cohort were used to estimate the sensitivity of TNBC patients with different prognostic statuses to immune checkpoint treatment. Results: Five immune-related genes associated with TNBC prognosis (IL6ST, NR2F1, CKLF, TCF7L2, and HSPA2) was identified and a prognostic evaluation model was constructed based on those genes. The respective areas under the curve of the prognostic nomogram model at 3 and 5 years were 0.791 and 0.859. The group with a lower nomogram score, with a better prognosis survival status and clinical treatment benefit rate. Conclusion: A prognostic model for TNBC that was closely related to the immune landscape and therapeutic responses was constructed. This model may help clinicians to make more precise and personalized treatment decisions pertaining to TNBC patients.
- 12 June 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (14) , 15704-15719
Open AccessConstruction of a prognostic model for triple‐negative breast cancer based on immune‐related genes, and associations between the tumor immune microenvironment and immunological therapy
Background: Triple-negative breast cancer (TNBC) is the subtype of breast cancer with the worst prognosis, and it is highly heterogeneous. There is growing evidence that the tumor immune microenvironment (TIME) plays a crucial role in tumor development, maintenance, and treatment responses. Notably however, the full effects of the TIME on prognosis, TIME characteristics, and immunotherapy responses in TNBC patients have not been fully elucidated. Methods: Gene Expression Omnibus and The Cancer Genome Atlas data were used to data analysis. Single-cell sequencing and tissue microarray analysis were used to investigate gene expression. The concentrations and distributions of immune cell types were determined and analyzed using the CIBERSORT strategy. Tumor immune dysfunction and exclusion score and the IMvigor210 cohort were used to estimate the sensitivity of TNBC patients with different prognostic statuses to immune checkpoint treatment. Results: Five immune-related genes associated with TNBC prognosis (IL6ST, NR2F1, CKLF, TCF7L2, and HSPA2) was identified and a prognostic evaluation model was constructed based on those genes. The respective areas under the curve of the prognostic nomogram model at 3 and 5 years were 0.791 and 0.859. The group with a lower nomogram score, with a better prognosis survival status and clinical treatment benefit rate. Conclusion: A prognostic model for TNBC that was closely related to the immune landscape and therapeutic responses was constructed. This model may help clinicians to make more precise and personalized treatment decisions pertaining to TNBC patients.
- Open Access
- 27 March 2020
- Published by Springer Nature in Research Square
Identification of key genes controlling docetaxel resistance in patients with breast cancer
Breast cancer is the most common malignant tumor in women. Chemotherapy is a very important part of its comprehensive treatment. Docetaxel is a commonly used chemotherapy drug in breast cancer treatment. However, some patients will develop drug resistance during use. To further explore this issue, we conducted an in-depth analysis on gene expression data of 24 breast cancer patients from GEO. Key module and hub genes were searched through WGCNA network construction, KEGG and GO function analysis, PPI network construction and other methods. Functional analysis revealed that the key module mainly related to drug transport events such as phagocytosis, cell-cell adhesion, and extracellular exosome. TCGA data were used to further verify these hub genes. Finally, we screened out 4 most important key genes, RPS2, EEF2, RPL15 and RPLP1, from 55 hub genes. These findings may highlight some therapeutic targets for predicting, avoiding or overcoming docetaxel resistance.
- 27 March 2020
- Published by Springer Nature in Research Square
Open AccessIdentification of key genes controlling docetaxel resistance in patients with breast cancer
Breast cancer is the most common malignant tumor in women. Chemotherapy is a very important part of its comprehensive treatment. Docetaxel is a commonly used chemotherapy drug in breast cancer treatment. However, some patients will develop drug resistance during use. To further explore this issue, we conducted an in-depth analysis on gene expression data of 24 breast cancer patients from GEO. Key module and hub genes were searched through WGCNA network construction, KEGG and GO function analysis, PPI network construction and other methods. Functional analysis revealed that the key module mainly related to drug transport events such as phagocytosis, cell-cell adhesion, and extracellular exosome. TCGA data were used to further verify these hub genes. Finally, we screened out 4 most important key genes, RPS2, EEF2, RPL15 and RPLP1, from 55 hub genes. These findings may highlight some therapeutic targets for predicting, avoiding or overcoming docetaxel resistance.
- 19 March 2019
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 33 (10) , 932-938
Proposed Modification of the 8th Edition of the AJCC Staging System for Gastric Cancer
Background: The American Joint Committee on Cancer (AJCC) staging system has been the standardized staging system for malignancies since the first edition in 1987. The 8th edition of gastric cancer was released in 2016, and is expected to be used in clinical practice in 2018. The aim of this study was to improve this new gastric cancer staging system. Methods: We conducted median overall survival analyses in a cohort of 8359 gastric cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2014) via Kaplan–Meier curves and log-rank tests, and proposed a modified staging system based on median OS. The concordance index (C-index) was conducted to evaluate the predictive accuracy. Results: Using the 8th AJCC staging system, the median OS of patients at the same stage varied widely between the different substages, especially in stage III. Despite the definitions of T, N, and M, substages in the modified staging system were regrouped based on median OS. The C-index of stage III patients with the modified staging system [0.579, 95% confidence interval (CI) 0.564–0.593] was higher than the 8th AJCC staging system (0.567, 95% CI 0.552–0.581). Moreover, we divided these patients into two groups according to their examined lymph node counts (≥15 or 1–14), and studied the effectiveness of the modified staging system in the two groups. Conclusions: The modified 8th AJCC staging system for gastric cancer proposed in this study generates better prognostic stratifications and may be evaluated for further update.
- 19 March 2019
- Published by Taylor & Francis in Journal of Investigative Surgery
- Vol. 33 (10) , 932-938
Proposed Modification of the 8th Edition of the AJCC Staging System for Gastric Cancer
Background: The American Joint Committee on Cancer (AJCC) staging system has been the standardized staging system for malignancies since the first edition in 1987. The 8th edition of gastric cancer was released in 2016, and is expected to be used in clinical practice in 2018. The aim of this study was to improve this new gastric cancer staging system. Methods: We conducted median overall survival analyses in a cohort of 8359 gastric cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2014) via Kaplan–Meier curves and log-rank tests, and proposed a modified staging system based on median OS. The concordance index (C-index) was conducted to evaluate the predictive accuracy. Results: Using the 8th AJCC staging system, the median OS of patients at the same stage varied widely between the different substages, especially in stage III. Despite the definitions of T, N, and M, substages in the modified staging system were regrouped based on median OS. The C-index of stage III patients with the modified staging system [0.579, 95% confidence interval (CI) 0.564–0.593] was higher than the 8th AJCC staging system (0.567, 95% CI 0.552–0.581). Moreover, we divided these patients into two groups according to their examined lymph node counts (≥15 or 1–14), and studied the effectiveness of the modified staging system in the two groups. Conclusions: The modified 8th AJCC staging system for gastric cancer proposed in this study generates better prognostic stratifications and may be evaluated for further update.